# A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

> **NCT06099782** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 147 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Renal Cell Carcinoma
- Melanoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab (+) Berahyaluronidase alfa
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06099782
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-26
- **Primary completion:** 2025-04-09
- **Final completion:** 2027-02-15
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06099782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06099782, "A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06099782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*